12 Best Quality Stocks to Buy and Hold for the Next Decade

9. Progyny, Inc. (NASDAQ:PGNY)

EPS Growth for the Next 5 Years: 40.83%

On June 22, Truist raised its price target on Progyny, Inc. (NASDAQ:PGNY) to $33 from $30 while maintaining a Buy rating following meetings with the company’s management team. According to the firm, discussions reinforced Progyny’s position as a highly differentiated provider of fertility benefits, supported by superior clinical outcomes, comprehensive member services, and a carefully managed provider network. Truist believes the company’s integrated approach continues to distinguish it from competitors and should enable it to maintain its leadership position as demand for fertility and family-building benefits continues to expand.

Earlier, on June 2, BofA increased its price target on Progyny, Inc. (NASDAQ:PGNY) to $31 from $29 while reiterating a Buy rating. The firm pointed to favorable fertility prescription trends and rising Google search activity related to reproductive treatments, suggesting utilization and assisted reproductive technology cycle growth are tracking ahead of expectations during the second quarter. BofA believes these indicators could translate into results that exceed current Wall Street estimates, reflecting sustained demand for Progyny’s comprehensive fertility benefits platform.

Founded in 2008 and headquartered in New York City, Progyny, Inc. (NASDAQ:PGNY) specializes in fertility, family-building, and women’s health benefits management. Progyny’s differentiated care model, favorable utilization trends, and projected five-year EPS growth rate of 40.83% position the company among the best quality stocks to buy and hold for the next decade.